Form 4: Intellia Therapeutics Director Jesse Goodman Reports Stock Transactions

Director Jesse Goodman reported the acquisition of 7,737 shares of common stock and 11,515 stock options, as well as the disposal of 19,453 shares of common stock.

Summary

• On June 12, 2024, Jesse Goodman, a director of Intellia Therapeutics, reported transactions involving the company's stock.
• Goodman acquired 7,737 shares of common stock at $0.00 and disposed of 19,453 shares.
• He also acquired options to purchase 11,515 shares of common stock at an exercise price of $25.85, which vest on the earlier of June 12, 2025, or the next annual meeting of stockholders.
• Following these transactions, Goodman directly owns 11,515 derivative securities.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it primarily reports transactions without expressing a clear positive or negative outlook. The disposal of shares is balanced by the acquisition of options.

Positives

• The acquisition of stock options by a director could be seen as a positive sign, indicating confidence in the company's future performance.

Negatives

• The disposal of 19,453 shares by a director could be interpreted negatively by some investors.

Risks

• The stock transactions by insiders are always subject to scrutiny and can influence investor sentiment.
• The vesting of the stock options is contingent on future events, which introduces uncertainty.

Future Outlook

The document does not contain explicit forward-looking statements, but the vesting of stock options implies an expectation of future value appreciation.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. Investors often monitor these filings for insights into management's perspective on the company's prospects.

Stakeholder Impact

• Shareholders may react to the reported transactions, potentially influencing the stock price.

Key Dates